<DOC>
	<DOC>NCT01802138</DOC>
	<brief_summary>Activated T cell were manufactured through in vitro T cell expansion of autologous T cell. We designed this study to determine the feasibility and safety of Activated T-lymphocyte cell therapy for refractory/relapsed neuroblastoma patients.</brief_summary>
	<brief_title>A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>Informed consent Age 21 years or younger Histologically confirmed neuroblastoma Progressive disease after standard treatment or relapsed patient ECOG scale (ECOGPS) â‰¤2 Expected survival at least 3 months Patients with autoimmune disease Patients with immunodeficiency Other malignancy 5 year prior to this study Severe organ dysfunction Severe allergic disease Severe psychiatric disorder Pregnancy or lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>refractory/relapsed neuroblastoma patients</keyword>
</DOC>